https://www.selleckchem.com/pr....oducts/eidd-2801.htm
rdial disease in this population is important, and further studies are needed to identify predisposing factors.Allergen immunotherapy (AIT) is the only disease-modifying treatment option for patients with type 1-mediated allergic diseases such as allergic rhinitis/rhinoconjunctivitis with/without allergic asthma. Although many innovations have been developed since the first clinical report of Noon et al in 1911, the improvement of clinical efficacy and tolerability of this treatment is still an important unmet need. Hence, much progre
Synes godt om
Kommentar
Del
